Melatonin and Abeta, Macular Degeneration and Alzheimers Disease: Same Disease, Different Outcomes? by Vladan, Bajic & Panfoli, Isabella
Hypothesis 
             
Medical Hypothesis, Discovery & Innovation  
Ophthalmology Journal 
 
 
 
Melatonin and Abeta, Macular Degeneration and Alzheimers 
Disease: Same Disease, Different Outcomes? 
Bajic Vladan1; Isabella Panfoli2 
¹Institute for Pharmaceutical Research and Development, & University of Belgrade, Belgrade, Serbia ²Department of Pharmacy, University of 
Genoa, Genova, Italy 
 
ABSTRACT 
Aging is the common denominator and the highest risk factor for macular degeneration and Alzheimers 
Disease (AD). Important pathological hallmarks common to both diseases are the presence of amyloid β 
(Aβ) in the senile plaques of the AD brain and in the drusen of age-related macular degeneration (AMD) 
patients, oxidative stress, and apoptotic cell death. Data suggest that a common pathogenic mechanism 
might exist between AMD and AD. Brain and eye depend on redox electrons from pyridinic and flavinic 
nucleotides to produce ATP, and reactive oxygen intermediates (ROI). Disorganization of mitochondrial 
structure and decline in mitochondrial oxidative phosphorylation (OXPHOS) functioning, as well as 
hypometabolism and alterations in mitochondrial DNA are aging features. Because ROI damage and 
mitochondrial dysregulation are prominent in AMD and AD and their relationship to the redox state is 
unclear we addressed a new hypothesis according to which the interaction of melatonin vs Aβ are 
intertwined to balance of the intra- and extra-mitochondrial energy production. This balance would be 
impaired by the ageing process and environmental/genetic factors, ultimately leading to AD and /or AMD.  
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INTRODUCTION  
Aging is a common risk factor in both age-related macular 
degeneration (AMD) and Alzheimer's disease (AD). The 
incidence of AMD is increasing in the aging population. The 
World Health Organization has stated that AMD is the most 
common form of blindness, with 1.75 million people in the US 
alone and 7 million people at risk [1]. AD is the most common 
dementia, doubling every 6 years after the age of 65. In 
Western countries, AD affects 1–3% of people aged 60–64 
years, and 3–12% of people aged 70–80 years. It is estimated 
that by the mid-century (2050) as much as 13,2 million people 
will be affected by AD in the US alone [2]. At the molecular level 
the pathognostic feature of AD is the accumulation of the 39-4 
amino acid long β-Amyloid (Aβ) peptide with more that 50% of 
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autopsy cases showing positive correlation. Aβ is also deposited 
in Drusen in AMD [3]. A prospective population-based 
Rotterdam Study found that the neuronal degeneration 
occurring in AMD and AD may, to some extent, represent an 
evidence of a possible epidemiological connection between the 
two diseases, but with different origin as for genetic risks [4]. 
Interestingly, there is a slight prevalence of the female gender 
towards AMD [5] and AD [6,7]. AMD and AD appear linked 
because the retina is part of the brain [8], deriving from the 
neural tube which is the precursor of CNS development; 
moreover, both have blood–tissue barriers. At present, chronic 
oxidative stress, inflammation and altered fatty acid 
metabolism are strongly linked to AMD [9,10] and also to  AD 
pathogenesis [11,12,13,14].   
 
Aging and the mitochondrion 
CNS and retina critically depend on oxygen (O2) supply [15], [16 
] and are sensitive to mitochondrial dysfunction [17 ]. However, 
mitochondrial disorders, human diseases characterized
 
by 
genetic defects of the oxidative phosphorylation (OXPHOS), 
affect the visual and the nervous system, even though these 
display a relative scarcity of mitochondria [17]. Mitochondrial 
dysfunctions are involved in pathologies associated with many 
diseases, such as, cancer, neurodegenerative diseases and 
aging. Aging is an incompletely understood process, in which a 
decline in mitochondrial function seems to be involved [18].  
Mitochondria display two membranes, the outer membrane 
allowing the passage of low molecular-weight substances 
thanks to porin expression, [19], and the inner membrane (IM) 
housing the electron transfer chain (ETC) and providing a highly 
efficient barrier to the ion flow. The IM forms invaginations 
called cristae where the ETC complexes I-IV are embedded. 
These enable the transfer of electrons from NADH and FADH 
synthesized by glycolysis, fatty acid oxidation and Tricarboxylic 
acid cycle (TCA) to reduce molecular O2 to water [20]. During 
electron transfer, energy is used to pump protons in the intra 
membrane space, which promotes ATP generation via OXPHOS, 
thanks to the nanomotor ATP synthase (complex V). Proton 
gradient generates a chemiosmotic proton potential driving 
ADP phosphorylation of  ADP to ATP (Figure 1). 
In yeast, oligomeric organization of ATP synthase was reported 
to be essential to the maintenance of the mitochondrial cristae 
architecture and to correlate with maximum energy conversion 
capability [21], with an age-associated decline in ATP synthase 
oligomers. Prior data [20,22,23,24] suggest that the electron 
transport chain (ETC) and F1Fo-ATP synthase are functionally 
expressed in extramitochondrial locations of the central 
nervous system, i.e: rod outer segment (OS) disks and isolated 
myelin vesicles [22, 23, 24]. While the mitochondrial proteome 
consists of more than 1,000 different proteins, many proteomic 
analyses of cellular membranes have found the exclusive 
expression of proteins from the five respiratory complexes [ 
(reviewed in Panfoli e al. (25)].  Moreover, the enzymes of the 
Tricarboxylic Acid (TCA) Cycle are catalytically active in the rod 
outer segment [20], in keeping with the knowledge that  many 
mitochondrial proteins possess dual or multiple localization 
[26] and that mitochondria are dynamic organelles, [27] . Ex 
vivo staining of the optic nerve and retina [22,23] with 
MitoTracker (MT), a fluorescent mitochondrial probe sensitive 
to proton potential , showed that a proton potential  is present 
in rod OS [28]. Mitochondria are currently believed to be 
central to a both life and death processes, such as energy 
production, and generation of reactive oxygen intermediates 
(ROI). However ROI would also be generated by the ectopic ETC 
coupled to ATP synthase. In fact an ETC not adequately coupled 
may generate ROI in turn oxidizing the polyunsaturated fatty 
acids of which the rod OS is rich. 
 
Figure 1. A schematic of the electron transport chain occurring in the 
inner mitochondrial  membrane. 
 
Aging is consistently related to oxidative damage of cellular 
macromolecules due to ROI production [26, 29]. Impairment in 
mitochondrial OXPHOS functioning, alterations in mitochondrial 
DNA (mtDNA), increased production of ROI, with 
disorganization of mitochondrial structure have been reported 
with aging [30]. During the electron transfer 0.4% to 5% of ETC 
participate in the formation of superoxide radicals (O2
•-
) [31], 
therefore ROI are a physiological by-product of the ETC. 
However, an increase in O2
•-
 production can activate the 
mitochondrial permeability transition pore [32], ultimately 
committing cell to death by apoptosis. A study by Ghosh et al 
[33.] showed that a redox shift precedes ROI changes in 3xTg-
AD mice, i.e. a more oxidized redox state and a lower 
antioxidant GSH defense precedes neuronal damage, and  the 
onset of cognitive defects. This means that even before cells 
accumulate harmful free radicals, they have changes in their 
reduction-oxidation reactions (redox). These results would 
explain why synapses go haywire long before people with 
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Alzheimer’s disease experience any problems with memory 
[13].  The findings that the “ redox shift precedes ROI changes‘’ 
in AD mice directly points mostly to our hypothesis showing 
that the melatonin-Aβaxis may alter mitochondrial energy 
balance during aging leading to AMD and or AD. Mitochondrial 
DNA polymorphisms that augment ATP production can reduce 
Aβ load in mice [34]. It was reported that mitochondrial DNA  
(mtDNA) mutations can promote aging also independently of  
enhanced ROI production [35] accumulation of mutations in 
mtDNA [35]. These were in turn associated to reduced life span, 
and to aging signs. 
In aging the ETC enzyme activity decrease, along with 
mitochondrial membrane potential. Parallely mitochondrial 
proteins and mtDNA are oxidatively damaged and there is a 
quantitative increase in mtDNA mutations. For example, Liang 
FQ et al., 2003 [36] showed that, when exposed to H2O2, human 
retinal pigmented epithelium (RPE) cells or rod outer segments 
display mtDNA but not nDNA damage. Authors concluded that 
the susceptibility of mtDNA to oxidative damage, and 
decreased anti-oxidant system capability provides a rationale 
for mitochondria based model of AMD [37, 38].   Using the 
same rationale Liang FQ et a., 2004 [37] observed that RPE cells 
pretreated with melatonin show a significant decrease in 
mtDNA damage. Another pathway to mitochondrial damage is 
through the action of oligomeric Aβ to induce alterations of  
intracellular Ca(2+) levels and to promote the excess 
accumulation of intracellular Ca(2+) into mitochondria, thus 
inducing the mitochondrial permeability transition pore 
opening [31]. Increasing evidence suggests that the amyloid 
precursor protein (APP) and Aβ accumulate in mitochondrial 
membranes, cause mitochondrial structural and functional 
damage by generating ROI, hindering normal neuronal 
functioning [39,40]. Inhibition of ATP synthase inhibits the 
electron transport and OXPHOS. Such inhibition can be induced 
by Aβ [41].  Rhein et al, 2009 [42] reported  that  Aβ also lead to 
impaired functions of the mitochondria in human 
neuroblastoma cells.  
 
Drusen and Amyloid plaques, different but the same? 
Extracellular protein deposits called drusen, accumulating 
between the RPE and photoreceptors, are a typical feature of 
non-neovascular AMD [43]. Drusen area and size positively 
correlate to risk of AMD progression [44]. Drusen are composed 
of acute phase proteins, complement components, 
proteglycans, apolipoproteins, metal ions (Fe, Zn, Cu), 
proteases ,cholinesterases, lipids [16,17,22], polysaccharides 
and ATP synthase subunit β [45] Some of these components are 
made by the eye itself, i.e.  retina, RPE and/or choroid [46]. 
Wang and Wang [47] showed that the most abundant 
molecules in Drusen where esterified  cholesterol and 
phosphatidine choline  which suggest abnormalities in the 
metabolism of cholesterol, a risk factor also in AD [48]. Isas et 
al, 2010 [49], found that among the amyloid forms (oligomers, 
protofibrils, fibrils) the non-fibrilar oligomers where the most 
abundant form of amyloid in Drusen. Recently, amyloid vesicles 
as forms pervading in Drusen have also been  reported in brains 
[50] of transgenic mice expressing human APP, suggesting the 
importance of APP processing in both eye and brain. Aβ 
accumulation has also been demonstrated in  association with 
drusen in eyes from AMD patients [51, 52, 53] mice models for 
AMD [50] and in RPE [3]. Recently, Barrett et al., 2012 [54] 
showed that cholesterol directly binds to the C99 fragment of 
APP. This fragment, the result of β-secretase cleavage, is 
important for AD pathology because it is cleaved by γ-secretase 
to release Aβ.  
A  causative role of oxidative stress and light exposure in the 
pathogenesis of AMD and other retinal degeneration has also 
been proposed [55 ] [56 ] [57] [58] [59] [60]. A critical role of 
SOD1 in protecting from AMD has been reported  [61]. The 
choroid and retina are  the highest oxygen-consuming tissues in 
the human body. The OS expressing oxygen-absorbing 
cytochrome c oxidase [22], would be at risk of oxidative stress 
oxidizing disk membranes, that contain high levels of 
polyunsaturated fatty acids. ROI are in fact a by-product of the 
ETC [17] [62] [63]. The result may be photoreceptor loss and 
visual impairment [64]. Inflammatory responses secondary to 
oxidative stress have been involved in age-related degenerative 
diseases. Oxidative stress induces the assembly of 
inflammatory protein complexes, the so-called inflammasomes, 
involving nod-like receptor protein 3 (NLRP3) [12]. The 
inflammasomes recognize danger signals, such as metabolic 
stress from ROI production, triggering inflammatory responses 
[12]. It was reported that misfolded protein aggregates such as 
amyloid-β can trigger NLRP3 inflammasome representing a 
pathogenetic mechanism in AD. Damaged mitochondria 
undergo digestion through mitophagy, a specialized form of 
autophagy, whose  impairment may cause aging [65]. 
Autophagic capacity seems to be  compromised in AD [66] and 
AMD [67]. Melatonin exerting its activity on Aβ in inflammation 
was  presented by the work of  Zhou et al. [68.] who found that 
microglia. i.e. the phagocytes of the nervous system, decrease 
superoxide anion production by impairing  NADPH oxidase 
assembly in cultures of microglia.   
 
APP/Aβ metabolism in the Eye and Brain 
Characteristic pathological features of AD are cerebral plaques 
with β-amyloid peptide and neurofibrillary tangles. However, as 
Aβ and tangles appear a normal finding in brains of non-
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demented individuals, these may be related to brain aging, 
independently of AD, suggesting their wider hypometabolic 
origin. The 2011 AD criteria proposes the presence of low CSF 
Aβ and decreased glucose utilization as AD biomarkers. Aβ is in 
small amount deposited in the brain [69] and in normal retina 
[51, 70] and the levels of these deposits increase during aging 
[71]. Johnson et al. [51] where the first to propose the 
pathogenic role of Aβ in AMD. Activated component 
complement component of RPE deposits where co localized to 
Aβ detected by using immunohistochemical technique. It was 
shown that Aβ can be detected in sub RPE basal deposits and 
neurovascular lesions in murine model of AMD [72].   
Accumulation of Aβ in the eye occurs primarily among the 
photoreceptor OS and in the interphase between the RPE and 
Bruch’s membrane. Indeed, an origin of drusen in OS has never 
been supposed, but considering their ability to manipulate O2 
should be taken into consideration. Such accumulation of Aβ on 
photoreceptor outer segments with age was confirmed in 
human retina using immunohistochemistry [71].  This implies 
that the accumulation of Aβ is associated with efficiency of RPE 
phagocytic process [3], but also through APP metabolism [73].  
Sarangarajan and Apte [74] showed that signaling pathways 
that upregulate melanization in the RPE may be  implicated in 
down-regulation of the rod OS phagocytosis by RPE, 
maintaining a balance between ingestion and 
degradation/recycling lowering metabolic load, suggesting a 
possible Aβ vs melatonin/melanin interaction in the balance of 
mitochondrial energy metabolism. Yoshida et al. [75]  showed 
that human RPE expresses constitutively all  of the genes that 
regulate Aβ production ,e.g., APP,α ,β,γ secretase and 
neprylisin.  
Melanization activating pathways may also modulate O2 
consumption by the photoreceptors, and the rate of 
photoisomerization events such that the net effect may be a 
reduction in drusen and/or lipofuscin accumulation. This 
interaction  may play a role in decreasing choroidal 
neovascularization. The hormone melatonin may have 
regulatory effects on APP metabolism. Interestingly, melatonin 
plays a fundamental role in retinogensis through APP 
metabolism [10,73,75]. Cultured RPE cells exposed to Aβ 
increase the expression of VEGF and decrease Pigment 
Epithelium-derived factor (PEDF, a potent antiangiogenic 
factor). Balance between these two molecules are important 
for healthy retina [76].  
Melatonin treatment inhibited normal levels of secretion of 
soluble APP (sAPP) in different cell lines by interfering with APP 
full maturation [77]. Melatonin also affects the mRNA level of 
APP in a cell type-specific manner. Additionally, administration 
of melatonin efficiently reduced Aβ generation and deposition 
both in vivo [78, 79] and in vitro [77]. Moreover, it has been 
reported that mitochondrial dysfunction is characteristic of Aβ-
induced neuronal toxicity in AD. A mitochondrial cascade 
hypothesis was proposed  postulating that Aβ production, and 
tau phosphorylation, are consequences of impaired 
mitochondrial function and hypometabolism.  Interestingly, the 
activity of mitochondrial enzymes (such as pyruvate- and 
ketoglutarate-dehydrogenase) as well as of some respiratory 
complexes (NADH:ubiquinone oxidoreductase, complex I, and 
cytochrome oxidase; complex IV, both partly coded by 
mitochondrial DNA) are reduced in mitochondria from AD 
subjects.  
 
HYPOTHESIS 
Considerng the findings of Panfoli et al., [25, 60] and others [42, 
31, 41, 80], the present paper proposes the hypothesis of a role 
for melatonin-Aβ axis in mitochondria, and  that the interaction 
of melatonin vs Aβ are intertwined to the balance of the  inter 
and extra mitochondrial energy production. This balance would 
be deregulated by the ageing process and other 
environmental/genetic factors, in turn leading to 
hypometabolism and neurodegenerative diseases characterized 
by protein deposition, such as AD and /or AMD. 
 
Evaluation and Disscussion of the Hypothesis 
Cumulative oxidative status plays a critical role to AMD and AD, 
both age related disorders [61]. A large gradient of oxygen 
towards the inner retina [81] fits with  an extra mitochondrial 
respiration [22]. Panfoli et al. [60] proposed a bioenergetic 
hypothesis drusen, which may originate through 
hypometabolism , in turn imbalancing clearance of proteins 
causing aggregation of peptides that accumulate [60]. In fact 
the OS, that contains high levels of polyunsaturated fatty acids 
and expresses oxygen-absorbing OXPHOS machinery  [82], 
outside mitochondria, is at risk of oxidative stress. ROI are in 
fact a by-product of the ETC [17] [62] [63]. ROI in turn may 
cause damage to RPE, increase the production of VEGF 
(Vascular Endothelial Growth Factor). Interestingly, Biochemical 
and histochemical analyses demonstrated that the labeled 
protein accumulating in the cytosol of Alzheimer degenerating 
neurons is the α-chain of the ATP synthase [83]. It is specifically 
observed in degenerating neurons, either alone or tightly 
associated with aggregates of tau proteins, suggesting that it is 
a new molecular event related to neurodegeneration. This may 
be the initiating factor in retinal degenerative diseases, but also 
in AD, both characterized by extracellular deposits of proteins. 
Extensive literature demonstrate melatonin antioxidant 
capacity [84 and refs. therein] both in vivo and in vitro. Its 
major action is maintenance of mitochondrial protein 
homeostasis. 
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 Interestingly, a modified model of the mitochondrial 
hypothesis for AD has been proposed, in which Aβ would cause 
neurotoxicity by interacting with mitochondrial targets or being 
itself intramitochondrial [85]. To strengthen the 
extramitochondrial idea,  Schmidt et al. [86] showed in vitro 
that ATP synthase subunit α is a binding partner for APP and Aβ 
on the surface of cultured hippocampal neurons and astrocytes 
indicating regulation of extracellular  ATP levels in the brain.  
Human drusen were found to contain Aβ and this was 
interpreted as an indication that the pathogenic pathways 
giving rise to drusen and AMD may be common in 
neurodegenerative diseases characterized by misfolded protein 
aggregation [53]. San Li Xing et al., 2012 [41] showed in amyloid 
precursor protein/presennillin-1 transgenic mice that the  α-
subunit of ATP synthase is associated with aggregates of Aβ 
proteins in amyloid plaques and when extracellular ATP 
generation was analyzed a inhibition pattern was observed by 
the aggregating Aβ peptide but not the level of ATP synthase 
subunit alpha on neurons. Chronic exposure to soluble Aβ may 
result in an impairment of energy homeostasis due to a 
decreased respiratory capacity of mitochondrial electron 
transport chain which, in turn, may accelerate neurons demise 
[41]. 
We have addressed that Aβ is a pathological component in AD 
and AMD and that Aβ and APP can be addressed to the 
mitochondrion. In respect to new insights of the 
extramitochondrial role in energy production for eyesight 
[20,25] in the OS of rods and that Aβ directly binds to theα 
subunit of the ATP synthase at the neuronal membranes and 
the demonstration of a number of complexes to capture and 
direct electrons and protons in the cell, melatonin shows 
probably a primary constituent in balancing the energy 
production in mitochondrial by acting upon the production of 
Aβ.    
In the introduction we showed that melatonin regulates APP 
metabolsim and can  efficiantly protect cells against Aβ toxicity, 
oxidative damage and cell death in vitro and  in vivo [47]. A 
recent study  showed that, chronic melatonin therapy in old 
Tg2576 mice initiated at 14 months of age failed to remove 
existing plaques, but also to prevent additional Aβ deposition 
[87]. Data on a diminished Aβ in melatonin-treated wild type 
mice [88] and reduced Aβ and protein nitration in melatonin 
treated Tg2576 mice also exist [89]. However, both studies 
concur in finding little evidence of the potent antioxidant 
effects of melatonin in the oldest mice. These findings indicate 
that melatonin has the ability to regulate APP metabolism and 
prevent Aβ pathology, but fails to exert anti-amyloid or 
antioxidant effects when initiated after the age of Aβ 
deposition. Although consistent conclusions were achieved, 
none of the related studies further explained how melatonin 
exerts its inhibitory effect on Aβ generation. One explanation of 
why aged mice are immune to melatonin might be in the 
process of melanogenesis, i.e. a failure in light/melanin/water 
system would be a cause rather than effect of AD has been 
proposed  [90].  The decrease in melanins ability to dissociate 
water (human photosynthesis) in AMD [91] and or AD has been 
proposed to be a cause of these diseases is a simplistic 
overview of the bioenegetic mechanism related to these 
diseases. In our view hypometabolism, likely due to decline in 
both intra- and extra-mitochondrial OXPHOS functioning, are 
indeed fundamental to the understanding of pathological 
processes in these related diseases and that there is a 
homeostatic mechanism of energy balance  related to 
relationship of melatonin versus Aβ through the regulation of 
mitochondrial fidelity. Melatonin protective role in AMD and 
AD may be a result of its action on mitochondrial physiology as 
suggested by its presence in mitochondrian circadian and 
seasonal variations in the brain and retina [92]. Locally 
produced melatonin in the surrounding of photoreceptors 
protects these cells thanks to its anti oxidant capacity or by 
activation of melatonin receptors [93]. Melatonin can increase 
membrane fluidity, as well as the activity of the ETC and ATP 
production, mitochondria membrane potential, while reducing 
oxidative stress [94]. Important pathological properties of Aβ, 
such as neurotoxicity and resistance to proteolytic degradation, 
depend on the ability of peptides to form β-sheet structures 
and/or amyloid fibrils [47]. Intervention in the Aβ aggregation 
process can be considered an approach to stopping or slowing 
the progression of AD and new investigation AMD. Melatonin 
can interact with Aβ40 and Aβ42 and inhibit the progressive 
formation of β-sheet and/or amyloid fibrils[95,96]. Melatonin 
could promote the conversion of β-sheets into random coils by 
disrupting the imidazole-carboxylate salt bridges and thus 
prevent Aβ fibrillogenesis and aggregation. It is therefore 
possible that by blocking the formation of the secondary β-
sheet conformation, melatonin may not only reduce 
neurotoxicity but also facilitate clearance of the peptide via 
increased proteolytic degradation.  
However, it is difficult to determine the extent of the 
contribution from each of these properties to the overall 
effects of melatonin treatment in vivo. In mammals melatonin 
exerts some of its functions through two specific high-affinity 
membrane receptors belonging to the superfamily of G-
protein-coupled receptors: MT1 and MT2. Decreased MT2 
immunoreactivity and increased MT1 immunoreactivity have 
been reported in the hippocampus of AD patients [97]. 
Contrary to these findings, a study by Pappolla et al. [98] 
demonstrated that melatonin protective activities against Aβ 
toxicity does not require its binding to membrane receptors, 
which strongly suggests that protection is a result of its 
antioxidant and anti amyloidegenic features. Melatonin 
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receptors have been found to modulate the visual function in 
mouse retina [99]. Numerous relationships are shown between 
melatonin and mitochondria in which protection of ETC 
proteins are crucial [94]. The hypothesis herein exposed has 
concentrated on the melatonin-Aβ axis in mitochondrial age 
related processes leading to AD and AMD. Still, there is a more 
complex view of this axis which is not in the scope of this paper, 
i.e. first, melatonin  functions exceeds its role as hormone that 
mediates signal ‘’darkness’’, second melanocytes are viewed as 
‘’neurons of the skin’’ with sensory and regulatory properties 
which can detect and transform external and internal 
signals/energy into organized regulatory networks for the 
maintenance of skin homeostasis [100] and  melanogenesis and 
its product melanin is by itself an pigment that has 
extraordinary properties [101].  The most important property is 
melanin participation in electron transfer reactions, reducing 
and oxidizing other molecules. Also, its key monomer, 
indolequinone, exhibits photodriven proton transfer cycles 
[102]. Melanin has showed radiotropism, melanized fungi are 
stimulated to grow in environments with high ionizing 
radiation, suggesting melanin may function as a broad-band 
radiation energy harvester, similiar to chlorophyll [103]. 
In summary, the mitochondrion is the prime cross road 
enabling electron transfer for all these transfer, and it is 
reasonable that proton flow may represent a fundamental 
physical force that sustains, drives, and informs all biological 
organization and dynamics, Nevertheless, electron driven 
transport of protons would not be confined to the 
mitochondrion but it seems to be a fundamental properties of 
many cell membranes.  
 
CONCLUSION 
Both AMD and AD are age-related neurodegenerative diseases. 
They share similar environmental risk factors thereby 
comprising smoking, hypertension, hypercholesterolemia, 
atherosclerosis, obesity, and unhealthy diet [104]. The 
pathogenesis is associated with increased oxidative stress, and 
hypometabolism with impaired proteasomal and lysosomal 
function that evoke formation of intra- and extracellular 
deposits, drusen, lipofuscin and amyloid plaques, features of 
both AMD and AD, even though with a different genetic 
background. These facts imply a role for intra but also for extra-
mitochondial OXPHOS. 
We have addressed that Aβ is a pathological component in both 
AD and AMD and that both Aβ and APP can be addressed to the 
mitochondrion. Moreover, ATP synthase α-subunit was found 
to be a component of AMD drusen that in turn contain Aβ. New 
insights on the role of extramitochondrial energy production 
suggest that it may support visual process [5, 8] in the rod OS 
and neuronal conduction in myelin vesicles [23, 105] and are 
consistent with the finding that the α-subunit of ATP synthase 
is associated with Aβ in Alzheimer's disease [35]. Melatonin 
seems to be a primary constituent in balancing the energy 
production in mitochondrial by acting upon the production of 
Aβ. In fact, melatonin can regulate APP metabolism and 
efficiently protect cells against Aβ toxicity, oxidative damage 
and cell death, by interacting with Aβ40 and Aβ42 and inhibit 
the progressive formation of β-sheet and/or amyloid fibrils 
[47]. 
Our hypothesis does to some extent comprise an epigenetic 
paradigm coupling aging as an underling mechanism of AD and 
AMD.A genetic background would be a “blue print’’ in which 
environmental, genetic and bioenergetic factors (intra- and 
extra-mitochondrial energy production) tending to act upon 
them, thus leading to AMD and /or AD. There is a direct link 
between perturbed energy states in neurons  and the retina 
[60] and creatinin and ATP metabolism. Also, there is a direct 
interaction between APP and the precursor of ubiquitous 
mitochondrial creatin kinase supporting a relationship between 
AD, cellular energy levels and mitochondrial function [106]. The 
same principle is allied to the retina and occurrence of AMD 
[60]. An understanding of the processes related to extra-
mitochondrial and intra-mitochondrial regulation of 
metabolism in the brain and in retina and their balance by a 
melatonin-Aβ axis may emerge as new therapeutic pathway for 
the therapy of both AMD and AD.  
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